Renaissance Capital logo

Stemline Therapeutics Priced, Nasdaq: STML

Biotech developing treatments that target cancer stem cells and tumor bulk.

Industry: Health Care

First Day Return: +18.0%

Industry: Health Care

Biotech developing treatments that target cancer stem cells and tumor bulk.
more less
IPO Data
IPO File Date 04/02/2012
Offer Price $10.00
Price Range $10.00 - $12.00
Offer Shares (mm) 3.3
Deal Size ($mm) $33
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/28/2013
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $33
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters New York, NY, United States
Founded 2003
Employees at IPO 8
Website www.stemline.com

Stemline Therapeutics (STML) Performance